Abstract
Introduction: Peripheral venous access (PVA) is recommended as a first-line vascular approach for therapeutic plasmapheresis with centrifugation methods but not filtration, which usually requires high blood flow. We evaluated the feasibility, efficacy, and safety of double-filtration plasmapheresis (DFPP) with PVA, using ultrasound guidance and regional citrate anticoagulation (RCA), i.e., PVA-RCA-DFPP in patients undergoing chronic DFPP. Secondly, we assessed the number of central venous catheters (CVCs) avoided. Methods: A single-center retrospective study evaluated 22 adult patients on chronic DFPP to perform PVA-RCA-DFPP. They were classified into 3 groups: successful (i.e., completion of sessions with PVA), primary failure (i.e., no sessions completed), secondary failure (i.e., ≥1 session with PVA completed but secondary return with CVC or arteriovenous fistula). Results: Among the 22 patients included (64% men), 7 patients (32%) were classified as primary failures (2 patient refusals, 5 inadequate PVAs), 1 patient (5%) as a secondary failure (due to uncomfortable venipunctures), and 14 patients (64%) as successful. In the successful group including 12 patients treated for chronic inflammatory demyelinating polyneuropathy (CIDP) and 2 patients for familial hypercholesterolemia (FH) (2 patients), 116 sessions were performed, with a median treated plasma volume of 4.3 L [IQR 3.6–4.6] (45 mL/kg) for a median duration of 134 min [IQR 122–144], and a median blood flow of 94 mL/min [IQR 87–103]. For the CIDP group, 90% of sessions achieved a plasma volume >1 TPV, and for the FH group 91% of sessions achieved an LDLc reduction >60%. Eleven sessions out of 116 (9%) were interrupted, mostly due to PVA dysfunction (5/11) and circuit clotting (4/11). Session interruptions decreased significantly between each patient’s first and following sessions (29% to 7%, p = 0.009). Conclusion: Chronic PVA-RCA-DFPP can be performed safely and efficiently, avoiding the use of CVCs.
References
1.
Barth D, Sanchez A, Thomsen AM, Garcia A, Malachowski R, Weldon R, et al. Peripheral vascular access for therapeutic plasma exchange: a practical approach to increased utilization and selecting the most appropriate vascular access. J Clin Apher. 2020;35(3):178–87.
2.
Connelly-Smith L, Tanhehco YC, Chhibber V, Delaney M, Eichbaum Q, Fernandez C, et al. Choosing wisely for apheresis. J Clin Apher. 2018;33(5):576–9.
3.
Putensen D, Leverett D, Patel B, Rivera J. Is peripheral access for apheresis procedures underutilized in clinical practice? A single centre experience. J Clin Apher. 2017;32(6):553–9.
4.
Mörtzell Henriksson M, Newman E, Witt V, Derfler K, Leitner G, Eloot S, et al. Adverse events in apheresis: an update of the WAA registry data. Transfus Apher Sci. 2016;54(1):2–15.
5.
Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc. 2006;81(9):1159–71.
6.
Salazar E, Garcia S, Miguel R, Segura FJ, Ipe TS, Leveque C. Ultrasound-guided peripheral venous access for therapeutic apheresis procedures reduces need for central venous catheters. J Clin Apher. 2017;32(4):266–9.
7.
Stolz LA, Stolz U, Howe C, Farrell IJ, Adhikari S. Ultrasound-guided peripheral venous access: a meta-analysis and systematic review. J Vasc Access. 2015;16(4):321–6.
8.
Mahon P, Grouchy K, McCartney H, Douglas K, Wu JK. Positive effects of ultrasound-guided peripheral IV insertion on pediatric sickle cell anemia/thalassemia patients receiving automated red cell exchange procedures or chronic transfusion therapy. J Clin Apher. 2021;36(1):143–8.
9.
Salazar E, Gowani F, Segura F, Passe H, Seamster L, Chapman B, et al. Ultrasound-based criteria for adequate peripheral venous access in therapeutic apheresis procedures. J Clin Apher. 2021;36(6):797–801.
10.
Rodríguez-Calero MA, Blanco-Mavillard I, Morales-Asencio JM, Fernández-Fernández I, Castro-Sánchez E, de Pedro-Gómez JE. Defining risk factors associated with difficult peripheral venous Cannulation: a systematic review and meta-analysis. Heart Lung. 1 mai 2020;49(3):273–86.
11.
Oliver LA, Oliver JA, Ohanyan S, Park W, Benelyahoo A, Vadivelu N. Ultrasound for peripheral and arterial access. Best Pract Res Clin Anaesthesiol. 2019;33(4):523–37.
12.
Tanhehco YC, Zantek ND, Alsammak M, Chhibber V, Li Y, Becker J, et al. Vascular access practices for therapeutic apheresis: results of a survey. J Clin Apher. 2019;34(5):571–8.
13.
Ipe TS, Marques MB. Vascular access for therapeutic plasma exchange. Févr. 2018;58(Suppl 1):580–9.
14.
Hafer C, Golla P, Gericke M, Eden G, Beutel G, Schmidt JJ, et al. Membrane versus centrifuge-based therapeutic plasma exchange: a randomized prospective crossover study. Int Urol Nephrol. 2016;48(1):133–8.
15.
Kes P, Janssens ME, Bašić-Jukić N, Kljak M. A randomized crossover study comparing membrane and centrifugal therapeutic plasma exchange procedures. Transfusion. 2016;56(12):3065–72.
16.
Ward DM. Conventional apheresis therapies: a review. J Clin Apher. 2011;26(5):230–8.
17.
Keklik M, Çelik S, Yıldızhan E. Comparison of centrifugal and membrane filtration modalities on therapeutic plasma exchange. J Clin Apher. 2022 Jun;37(3):217–222.
18.
Abe T, Matsuo H, Abe R, Abe S, Asada H, Ashida A, et al. The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis. Ther Apher Dial. 2021;25(6):728–876.
19.
Agishi T, Kaneko I, Hasuo Y, Hayasaka Y, Sanaka T, Ota K, et al. Double filtration plasmapheresis. Ther Apher. 2000;4(1):29–33.
20.
Hirano R, Namazuda K, Hirata N. Double filtration plasmapheresis: review of current clinical applications. Ther Apher Dial. 2021;25(2):145–51.
21.
Rozga J, Piątek T, Małkowski P. Human albumin: old, new, and emerging applications. Ann Transplant. 2013;18:205–17.
22.
Buckley MS, Knutson KD, Agarwal SK, Lansburg JM, Wicks LM, Saggar RC, et al. Clinical pharmacist-led impact on inappropriate albumin use and costs in the critically ill. Ann Pharmacother. 2020;54(2):105–12.
23.
Buckley MS, Agarwal SK, Lansburg JM, Kopp BJ, Erstad BL. Clinical pharmacist-led impact on inappropriate albumin utilization and associated costs in general ward patients. Ann Pharmacother. 2021;55(1):44–51.
24.
Lanzoni M, Candura F, Calizzani G, Biffoli C, Grazzini G. Public expenditure for plasma-derived and recombinant medicinal products in Italy. Blood Transfus Trasfus Sangue. 2013;11(Suppl 4):s110–117.
25.
Moranne O, Chauvel F, Pambrun E, Ahmadpoor P, Prelipcean C, Wuillai A, et al. Tandem hemodialysis and DFPP: procedure, safety and cost-effectiveness in patients requiring chronic hemodialysis and lipid apheresis. J Clin Apher. 2022;37(5):476–88. https://onlinelibrary.wiley.com/doi/abs/10.1002/jca.22005.
26.
Stegmayr B, Wikdahl AM. Access in therapeutic apheresis. Ther Apher Dial. 2003;7(2):209–14.
27.
Waitz G, Atiye S, Gauly A, Prophet H. Comparison of plasma separation using centrifugation or filtration for MONET lipoprotein apheresis in patients with cardiovascular disease and severe dyslipidemia. Ther Apher Dial. 2022;26(6):1281–8.
28.
Ho QY, Teh SP, Thangaraju S, Teo SH, Tan HK, Abdul Rahman MB, et al. Regional citrate anticoagulation during double-filtration plasmapheresis in kidney transplant recipients: a single-center retrospective cohort study. Blood Purif. 2022;51(4):376–82.
29.
Peng X, Xie X, Yin J, Yu S, Zhang C, Zhao S. Anticoagulation effect and safety observation of regional citrate anticoagulation for double-filtration plasmapheresis in critical patients. Blood Purif. 2020;49(5):542–9.
30.
Lee G, Arepally GM. Anticoagulation techniques in apheresis: from heparin to citrate and beyond. J Clin Apher. 2012;27(3):117–25.
31.
Yuan F, Li Z, Li X, Liu H. Application of regional citrate anticoagulation in membrane therapeutic plasma exchange. Int Urol Nephrol. 2020;52(12):2379–84.
32.
Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher. 2019;34(3):171–354.
33.
Staley EM, Hoang ST, Liu H, Pham HP. A brief review of common mathematical calculations in therapeutic apheresis. J Clin Apher. 2019;34(5):607–12.
34.
van Loon FHJ, van Hooff LWE, de Boer HD, Koopman SSHA, Buise MP, Korsten HHM, et al. The modified A-DIVA scale as a predictive tool for prospective identification of adult patients at risk of a difficult intravenous access: a multicenter validation study. J Clin Med. 2019;8(2):E144.
35.
Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med. 2001;29(4):748–52.
36.
Kissling S, Legallais C, Pruijm M, Teta D, Vogt B, Burnier M, et al. A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges. BMC Nephrol. 2017;18(1):81.
37.
Kim DH, Park JI, Lee JP, Kim YL, Kang SW, Yang CW, et al. The effects of vascular access types on the survival and quality of life and depression in the incident hemodialysis patients. Ren Fail. 2020;42(1):30–9.
38.
Moura A, Madureira J, Alija P, Fernandes JC, Oliveira JG, Lopez M, et al. Type of vascular access and location in online hemodiafiltration and its association with patient's perception of health-related quality of life. Juin. 2014;15(3):175–82.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
